GlassScriptPhysician profile
Carlos A Avila
NPI 1740921030
$1,477.41
in general payments reported to CMS, 2019-2025
23 companies · $511 in 2025
The $511 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.03 · 2023: $332 · 2024: $574 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $182.65 | 2023-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.37 | 2023-2025 | Jardiance, Synjardy, Ofev |
| Phathom Pharmaceuticals, INC. | $140.99 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $125.90 | 2023-2024 | Rexulti |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Lilly USA, LLC | $110.37 | 2023-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $106.10 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $78.20 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $72.20 | 2022-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $51.09 | 2023 | Livtencity |
| Pfizer INC. | $49.54 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $48.17 | 2023-2025 | Austedo Xr, Austedo |
| Mylan Specialty L.P. | $34.93 | 2022-2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.17 | 2025 | Caplyta |
| Boston Scientific Corporation | $23.89 | 2025 | Watchman Access System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.84 | 2024 | |
| Tactile Systems Technology INC | $19.90 | 2024 | Flexitouch Plus, Entre Plus |
| Amgen INC. | $17.99 | 2024 | Repatha |
| Urovant Sciences INC | $17.66 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.36 | 2023 | Ztlido |
| Exact Sciences Corporation | $15.38 | 2024 | Cologuard Collection Kit |
| Baxter Healthcare | $13.94 | 2022 | |
| Abbvie INC. | $12.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.